This study systematically summarizes the four major mechanisms underlying Daratumumab treatment failure, with particular emphasis on the timing of anti-drug antibody detection and clinical management strategies, providing direct evidence for optimizing individualized therapy in multiple myeloma and AL amyloidosis.
Literature Overview
The article titled “Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss,” published in the journal Antibodies, systematically explores the potential mechanisms limiting the efficacy of Daratumumab in treating multiple myeloma and AL amyloidosis. The study focuses on two key factors—anti-Daratumumab antibodies (ADAs) and urinary drug loss—and, drawing on experiences from other monoclonal antibody therapies, proposes four resistance pathways. It further analyzes clinical challenges and optimization strategies for ADA detection. The article underscores the importance of standardized ADA monitoring in patients with suboptimal responses or infusion reactions, offering theoretical support for clinical decision-making.Background Knowledge
Currently, multiple myeloma and AL amyloidosis continue to face high relapse rates and treatment resistance, particularly in advanced patients. Although Daratumumab significantly improves prognosis, approximately one-third of patients fail to achieve deep, durable responses. While its target, CD38, is highly expressed on plasma cells, it may be downregulated or undergo antigen escape during therapy, leading to resistance. Additionally, upregulation of complement-inhibitory proteins such as CD55 and CD59 weakens Daratumumab-mediated complement-dependent cytotoxicity (CDC). More critically, the drug's pharmacokinetics are influenced by multiple factors, including urinary loss due to renal dysfunction and anti-drug antibodies produced by the host immune system. Although Daratumumab is a fully human IgG1 antibody with theoretically low immunogenicity, clinical observations of reduced efficacy or infusion reactions in some patients suggest that ADA may play a role. However, current detection methods, often conducted during treatment, are subject to interference from circulating drug, leading to false-negative results. Thus, accurately assessing immunogenicity remains a key challenge in current research. This study addresses this clinical dilemma by systematically reviewing resistance mechanisms and proposing optimal time windows and strategies for ADA monitoring, offering new insights into improving treatment durability.
Research Methods and Experiments
The authors conducted a systematic literature search (via PubMed, Google Scholar, Web of Science, and Cochrane Library) to identify seven published clinical studies involving Daratumumab monotherapy or combination regimens, assessing the incidence and neutralizing capacity of anti-Daratumumab antibodies (ADAs). The study designs included Phase I–III clinical trials, covering various administration routes (intravenous and subcutaneous), different patient populations (newly diagnosed and relapsed/refractory multiple myeloma, NK/T-cell lymphoma), and treatment settings. ADA detection primarily relied on ELISA, though the timing of testing varied significantly across studies, resulting in substantial heterogeneity. The authors specifically noted that high concentrations of circulating Daratumumab can form complexes with ADAs, masking detection signals and leading to false-negative results—a phenomenon particularly prominent during active treatment.Key Conclusions and Perspectives
Research Significance and Prospects
This study systematically integrates multiple resistance mechanisms of Daratumumab from clinical pharmacology and immunological perspectives, particularly highlighting the dynamic “time–drug–antibody” relationship in ADA detection. For drug development, it suggests designing more resistance-resistant antibodies or combining with immunomodulatory strategies. For clinical monitoring, it recommends delayed sampling after treatment failure, infusion reactions, or before re-challenge to enhance ADA detection and guide therapy adjustments. For disease modeling, gene-knockout or humanized mouse models could simulate resistance phenotypes to explore mechanisms and interventions.
Conclusion
This study provides a systematic interpretation of Daratumumab resistance mechanisms, emphasizing the potential roles of anti-drug antibodies and urinary loss in treatment failure. Although current reports indicate low ADA incidence, inappropriate testing timing may lead to significant underestimation. From bench to bedside, this finding calls for the establishment of standardized ADA monitoring protocols, particularly testing 3–6 months after drug discontinuation to accurately reflect immunogenic risk. For patients with multiple myeloma and AL amyloidosis, especially those with renal impairment, a comprehensive assessment of drug exposure, antigen expression, and host immune status is essential for individualized management. Future research requires larger, prospective studies to validate the predictive value of ADAs on treatment outcomes and to explore intervention strategies such as treatment interruptions or combination immunosuppression. This work lays a theoretical foundation for optimizing the durability of monoclonal antibody therapies and represents a significant step toward precision hematologic oncology treatment.
